An assessment of the benefits of the diffusion of an innovation

A benefit-cost analysis of an innovative pharmaceutical in a relatively small market in the United Kingdom was carried out. The market was that for anti-tuberculosis drugs. The impact of the innovation, as it proceeded through its commercial life cycle, on competing products and on alternative hospitalisation therapy was evaluated. Despite the high cash price of the product relative to those it replaced this price was dwarfed by the benefits provided.